While Novogaia is building a next-gen discovery platform, CEO Tess Bevers emphasizes that the company's primary focus must be advancing its first drug candidates. For early-stage biotechs, the tangible value lies in getting molecules further down the pipeline, not just in perfecting the underlying technology.

Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

A venture capital partner reveals a specific evaluation framework focusing on seven key areas: Team, Total Addressable Market (TAM), Traction, Technology, Transformation (industry impact), Timing (why now?), and the potential for a 10x return. This provides a clear roadmap for founders seeking funding.

Small biotechs must avoid becoming too attached to their initial lead compounds. They should adopt a 'first pancake' mindset, recognizing the first attempt may need to be discarded. This requires a professional, decision-driving approach over an emotional, project-tracking one.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

Facing capital constraints, biotech companies must make a strategic choice. They can either dilute ownership by raising more venture capital or dilute their pipeline by partnering a secondary asset to fund their lead program. This "equity vs. assets" framework forces a clear-eyed decision on capital strategy.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.